Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q4 2018 · 10-K
Revenue—
Net Income-$4.08M-$4.08MN/M vs Q4 2017 EPS Diluted-$0.19-$0.19N/M vs Q4 2017 Operating Income-$4,078,000N/M Operating Cash Flowderived-$2,603,600N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,603,600— ended Mar 31, 2018 · filed Jun 26, 2018 · 87 d after period end